« Return to News | Awards & Advancement

Syndax appoints Pappas to board of directors

Friday, April 6, 2012 03:26 PM

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company based in Waltham, Mass., has added Arthur M. Pappas to the ranks of its board of directors.

Pappas is the founder and managing partner of Pappas Ventures, a Research Triangle Park, N.C.-based venture capital firm that invests nationally in the life science industry. Pappas and his team of investment, biotechnology and medical experts manage over $350 million and oversee investments in more than 40 portfolio companies. 

Prior to founding Pappas Ventures in 1994, he held senior level leadership positions at several multinational pharmaceutical companies, including Glaxo Holdings, Abbott International, Merrell Dow Pharmaceuticals and Dow Chemical Company. In addition to Syndax, Mr. Pappas is currently a director of Afferent Pharmaceuticals, CardioDx, CeNeRx, Chimerex, CoLucid and TyRx. He was also involved in Plexxikon, which was sold to Daiichi Sankyo last year.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.